<?xml version="1.0" encoding="UTF-8"?>
<p id="Par37">One of the potential therapeutic antibodies is TCN-032, which has passed phase I and II clinical trials. TCN-032 recognizes the M2e2â€“6 epitope [
 <xref ref-type="bibr" rid="CR37">37</xref>] and may provide immediate immunity against influenza A infection [
 <xref ref-type="bibr" rid="CR99">99</xref>]. Another potential therapeutic antibody is anti-M2e antibody Z3G1, which has been shown to protect mice applied therapeutically at different time points after infection [
 <xref ref-type="bibr" rid="CR128">128</xref>].
</p>
